
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…
Founded: 2023
Headquarters: Villejuif, Île-de-France, France
Focus: AI-powered precision oncology platform for drug development
Flagship products: O-Predict; O-Validate
Notable funding: Seed round (Dec 2024); ~€11M–€15M total raised
28 employees
Cancer drug development, with an emphasis on colorectal and pancreatic cancers
2023
Biotechnology Research
≈€11,000,000
Seed round announced Dec 3, 2024; reporting cites nondilutive support from Bpifrance and total capital raised to date near €15M in some sources.
“Bpifrance; Singular; additional investors recorded (Amazon Web Services, HCVC, SistaFund, Speedinvest, Verve Ventures)”
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
80,000+
Open Roles
4,000+
New This Week
| Company |
|---|
Technical Interview (45 minutes call) – A deep dive into your technical skills and expertise relevant to the role.
Technical Case (30 minutes presentation + discussion) - A case study or problem-solving exercise to assess your strategic thinking and analytical abilities. If possible this can be done in person.
Founder Interview: As final step of our recruitment process, you will meet the founders of Orakl Oncology in person at our office. This meeting is an opportunity for the founders to assess cultural fit and ensure alignment with our company values.